Organization
Cancer Centre of Southeastern Ontario/Queen's University
4 abstracts
Abstract
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with resectable pancreatic ductal adenocarcinoma.Org: Cancer Research Center of Marseille (CRCM), Digestive and Medical Oncology Department, Paul Brousse Hospital, Cancer Centre of Southeastern Ontario/Queen's University, Paoli-Calmettes Institute,
Abstract
Tandem duplicator phenotype: A novel targetable subgroup in pancreatic cancer?Org: Princess Margaret Cancer Centre, Ontario Institute for Cancer Research, Toronto, ON, Canada, Trinity St. James’s Cancer Institute, University of Toronto, University Health Network,
Abstract
Impact of positive resection margins on recurrence and survival following resection and adjuvant chemotherapy in pancreatic cancer: Results of the PRODIGE 24-CCTG PA-6 trial.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Lorraine Cancer Institute, Nancy N and J C Lewis Cancer and Research Pavilion, France, Institut de Cancérologie de Lorraine,
Abstract
Camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma: A single-arm, multicenter, exploratory study.Org: Cancer Centre of Southeastern Ontario/Queen's University, The First Hospital of Jilin University, Changchun, Jilin Province, China, Changchun, China,